Medication Safety

Ozempic Side Effects: Common, Serious, and How to Manage Them

The most common Ozempic (semaglutide) side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. Per the FDA label these are usually mild to moderate and ease as the dose is increased slowly. Less common but serious risks include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors. Discuss any persistent or severe symptoms with your prescriber.

Side Effects at a Glance

Common / Manageable

NauseaThe most frequently reported reaction; tends to be worst after a dose increase and to lessen over time.
VomitingReported in clinical trials; more likely at higher doses or with large, high-fat meals.
DiarrheaCommon, especially early in treatment.
Abdominal painGenerally mild; persistent or severe pain should be reported promptly.
ConstipationCommon; related to slowed gastric emptying.
Decreased appetite / dyspepsiaExpected with the medication’s mechanism; can reduce food and fluid intake.

Serious / Rare

Thyroid C-cell tumors (boxed warning)Semaglutide caused thyroid C-cell tumors in rodents. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Human risk is undetermined.
PancreatitisAcute pancreatitis has been reported. Severe, persistent abdominal pain (sometimes radiating to the back) warrants prompt evaluation.
Gallbladder diseaseCholelithiasis and acute gallbladder disease have occurred, particularly with rapid weight loss.
Acute kidney injuryDehydration from vomiting/diarrhea can worsen kidney function; staying hydrated matters.
HypoglycemiaRisk is increased when used with insulin or a sulfonylurea; dose adjustments may be needed.
Diabetic retinopathy complicationsIn the SUSTAIN-6 trial, retinopathy complications occurred more often with semaglutide in people with a history of diabetic retinopathy.
Hypersensitivity reactionsSerious allergic reactions including anaphylaxis and angioedema have been reported; stop and seek care if they occur.

Why these side effects happen

Ozempic is a GLP-1 receptor agonist. It slows how fast the stomach empties and signals fullness to the brain. That same mechanism that reduces appetite is what drives most of the gastrointestinal side effects. Because the effect is dose-dependent, the FDA-approved dosing starts low (0.25 mg weekly) and is titrated up gradually specifically to limit nausea and other GI symptoms. This is education, not a dosing recommendation — your prescriber sets your titration schedule.

Managing common side effects

General, label-consistent strategies that many people and clinicians use to reduce GI symptoms include the following. None replace medical advice, and persistent or severe symptoms should be reported to your prescriber.

Eat smaller, more frequent meals and stop eating when you feel full.
Limit greasy, fried, and very high-fat foods, which tend to worsen nausea.
Stay hydrated, especially if you have vomiting or diarrhea, to reduce the risk of kidney strain.
Do not increase your dose faster than your prescriber directs; slower titration usually means fewer symptoms.
Tell your prescriber about severe or persistent abdominal pain, signs of dehydration, or vision changes.

When to call your prescriber

Seek prompt medical attention for severe, persistent abdominal pain (possible pancreatitis), symptoms of a gallbladder attack, signs of an allergic reaction (swelling, trouble breathing), persistent vomiting with signs of dehydration, or any new or worsening vision problems. Never start, stop, or change your dose without talking to the clinician who prescribed it.

The Centurion companion approach

Centurion Coach is built to sit alongside your prescribed GLP-1, not replace it or your clinician. Two areas where a companion app helps: tracking GI symptoms against your titration so you and your prescriber can see patterns, and protecting lean muscle. Rapid weight loss on a GLP-1 can include loss of muscle along with fat, so Centurion emphasizes adequate protein intake and resistance training to support muscle retention. This is general nutrition and training education — it does not treat side effects or change how your medication works, and any medical decisions stay with your prescriber.

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.

FAQ

Frequently Asked Questions

For most people the gastrointestinal side effects (nausea, diarrhea) are most noticeable in the first days to weeks after starting or after a dose increase, then improve as the body adjusts. The FDA-approved dosing is titrated slowly for this reason. If symptoms are severe or do not improve, contact your prescriber.

According to the FDA prescribing information, the most common adverse reactions are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. Decreased appetite is also expected given how the medication works.

Nausea itself is usually mild to moderate and tends to ease over time. It becomes a concern if it leads to persistent vomiting and dehydration, which can strain the kidneys. Tell your prescriber if nausea is severe, does not improve, or stops you from keeping fluids down.

The label carries a boxed warning for thyroid C-cell tumors (seen in rodents; it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2). Other serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia when combined with insulin or a sulfonylurea, diabetic retinopathy complications, and serious allergic reactions.

Common, label-consistent steps include eating smaller meals, limiting high-fat foods, staying hydrated, and following your prescriber’s titration schedule rather than increasing the dose quickly. These do not replace medical advice. Report severe or persistent symptoms to your prescriber.

Sources

Ozempic (semaglutide) injection — Prescribing Information — FDA / DailyMed
AGA Clinical Guidance: management of patients taking GLP-1 receptor agonists — American Gastroenterological Association

Reviewed for accuracy by the Centurion Metrics Clinical Team. Last reviewed June 15, 2026. Content is sourced from FDA prescribing information and major clinical bodies.